Oxford Vacmedix moves cancer vaccines forward with $12.5M from South Korea, China
South Korea and Chinese investors have sunk a collective $12.5 million into an Oxford University spinout that promises a more efficient and cheaper way to make cancer vaccines.
The financing round potentially opens up the Korean market for Oxford Vacmedix (OVM), which already out-licensed its recombinant overlapping peptide technology to a joint venture registered in Hong Kong. Much of the science, however, actually takes place in Changzhou (between Nanjing and Shanghai), where an OVM center has been conducting early-stage validation of the technology developed by scientific founder and CSO Shisong Jiang.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.